CN1299733C - Chinese medicine and its preparing method and use - Google Patents
Chinese medicine and its preparing method and use Download PDFInfo
- Publication number
- CN1299733C CN1299733C CNB2005100421660A CN200510042166A CN1299733C CN 1299733 C CN1299733 C CN 1299733C CN B2005100421660 A CNB2005100421660 A CN B2005100421660A CN 200510042166 A CN200510042166 A CN 200510042166A CN 1299733 C CN1299733 C CN 1299733C
- Authority
- CN
- China
- Prior art keywords
- liver
- ethanol
- group
- capsule
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The present invention relates to a traditional Chinese medicine which is characterized in that the present invention contains 10 to 40% of red sage roots, 5 to 30% of haws, 10 to 35% of water plantain, 5 to 20% of astragalus roots, 5 to 15% of white peony roots and 3 to 20% of red rice according to weight percent. The traditional Chinese medicine of the present invention has the efficacy of dispersing blood clots, eliminating phlegm, strengthening a spleen, dispersing the stagnated liver energy and promoting the metabolism of fat deposited in vivo and liver cells, and the purpose of treating fatty liver, hyperlipemia, adiposis and atherosclerosis of arteries blood vessels can be achieved. The present invention has the advantages of obvious efficacy, little toxic and side effect, convenience for taking in, stable and reliable quality and very good clinical popularization and application value.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of diseases such as fatty liver, hyperlipemia, obesity, arteries is atherosis and preparation method thereof.
Background technology
In recent years, the sickness rate of fatty liver is constantly soaring.It is reported that the sickness rate of 30～50 years old young and middle-aged fatty liver is about 10% in China big and medium-sized cities; Crowd's pathogenesis of fatty liver rate more than 50 years old is 24.6%; The sickness rate of obese people, type ii diabetes patient and alcoholic is higher, and its hazardness is also more and more, becomes the second largest hepatopathy that is only second to viral hepatitis.Fatty liver and hepatic fibrosis and liver cirrhosis usually successively take place or merge to exist, and about 25% Patients with Fatty Liver merges and hepatic fibrosis occurs, and liver cirrhosis takes place 1.5%～8% patient.Along with the development of Chinese national economy, the change of the change of life style and dietary habit and structure, the increasing rapidly and, had to cause compatriots' great attention of pathogenesis of fatty liver by its trend that develops concurrent other hepatopathys.
Fatty liver is in the hepatocyte that causes of a variety of causes due to the athero.From the eighties in 20th century, along with popularizing of ultrasonic and CT examination, fatty liver finds to cause gradually clinical concern as a kind of common iconography.Schaffner in 1986 etc. propose after fatty liver disease (the fatty liver disease) notion just real with fatty liver as a kind of clinical independence disease.Secular excessive drinking and high fat diet are the main causes that forms fatty liver, according to estimates, 1,500 ten thousand～2,000 ten thousand people excessive drinking is arranged in the world approximately, 10%～20% alcoholic liver disease that has in various degree wherein, the sickness rate of China nineties than the eighties before 30 times of surges, still in rising trend at present, and age of onset is more and more littler.Alcoholic fatty liver is if untimely treatment can develop into alcoholic hepatitis, alcoholic fibrosis, alcoholic cirrhosis and hepatocarcinoma.
At present, main clinically medicine has: (1) choline and L-carnitine, the unsaturated lecithin of (2) multivalence, (3) S-adenosylmethionine, (4) antioxidant, reduced form GSH, taurine, vitamin E, selenium organic compound, (5) lipid lowerers etc.Though some medicine has been used for the treatment of fatty liver, still there is not satisfactory therapeutic effects so far, the clinical drug uncertain therapeutic efficacy that has is cut, and what have also has certain side effect.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine and preparation method thereof and the application in preparing the atherosis medicine of treatment fatty liver, hyperlipidemia, obesity and arteries, to remedy the above-mentioned deficiency of prior art.
A kind of Chinese medicine is characterized in that containing Radix Salviae Miltiorrhizae, Fructus Crataegi, Rhizoma Alismatis, the Radix Astragali, the Radix Paeoniae Alba, Monas cuspurpureus Went, and their percetage by weight scope is: 10～40%, 5～30%, 10～35%, 5～20%, 5～15%, 3～20%.
Above-mentioned preparation method of Chinese medicine is characterized in that taking by weighing Chinese crude drug Radix Salviae Miltiorrhizae, Fructus Crataegi, Rhizoma Alismatis, the Radix Astragali, the Radix Paeoniae Alba and Monas cuspurpureus Went; Extract red rooted salvia with ethanol or aquiferous ethanol earlier, filter, get filtrate A; Reuse water extraction medicinal residues filter, and get liquor B; With ethanol or aquiferous ethanol co-extracted Fructus Crataegi, Rhizoma Alismatis, the Radix Astragali, the Radix Paeoniae Alba and Monas cuspurpureus Went medical material, filter, get liquor C; Reclaim ethanol from liquor C, concentrate extractum D; D adds entry to extractum, leaves standstill, and is centrifugal, gets supernatant E and precipitation F, will precipitate the F drying, as active ingredient I; Supernatant E and liquor B are merged, by resin column, wash with water earlier to the molish reaction and be negative, it is colourless that reuse ethanol or aquiferous ethanol are washed till effluent, collects eluent, this eluent is merged with filtrate A, and recovery ethanol, concentrate drying is as active ingredient II; Active ingredient I and II are mixed, pulverize.
The application of above-mentioned Chinese medicine in the medicine of preparation treatment fatty liver.
The application of above-mentioned Chinese medicine in the medicine of preparation treatment hyperlipemia.
The application of above-mentioned Chinese medicine in the medicine of preparation treatment obesity.
The application of above-mentioned Chinese medicine in preparing the atherosis medicine of treatment arteries.
Medicine of the present invention has the effect of blood stasis dispelling expectorant, spleen invigorating soothing liver-QI, can make the fatty homergy that is deposited in body and the hepatocyte, reaches treatment fatty liver, hyperlipemia, obesity and the atherosis purpose of arteries.Effect is obvious, and toxic and side effects is little, taking convenience, and steady quality is reliable, has good clinical and promotes the use value.
The specific embodiment
Take by weighing Radix Salviae Miltiorrhizae 3000g, Fructus Crataegi 2500g, Rhizoma Alismatis 2000g, Radix Astragali 1250g, Radix Paeoniae Alba 750g, Monas cuspurpureus Went 500g; Wherein Radix Salviae Miltiorrhizae is with 95% ethanol lixiviate 2 times, and each used alcoholic acid weight is 8 times of Radix Salviae Miltiorrhizae, each 2 hours, filter, filtrate A; The medicinal residues water is in 60 ℃ of warm macerating 3 times, and the weight of each institute water is 10 times of Radix Salviae Miltiorrhizae, each 1.5 hours, filter, liquor B.All the other five kinds of medical materials are 8 times of five kinds of medical material gross weights with 70% alcohol reflux 2 times, each used alcoholic acid weight, each 1.5 hours, filter, liquor C; Reclaim ethanol from liquor C, in 70 ℃ of decompressions (vacuum :-0.08Mpa) concentrate extractum D, add water to 3 times of five kinds of medical material gross weights to extractum D, leave standstill, centrifugal, supernatant E and precipitate F, will precipitate the F drying, as active ingredient I; Supernatant E and liquor B are merged, by the good D101 macroporous adsorptive resins of pretreatment, wash with water earlier to molish reaction and be negative, it is colourless that reuse 75% ethanol (eluant) is washed till effluent, collect eluent, this eluent and filtrate A are merged, reclaim ethanol and be condensed into extractum, in 70 ℃ of decompressions (vacuum :-0.08Mpa) drying, as active ingredient II; Active ingredient I and II are mixed, pulverize, cross sieve No. 5, add 62.5g micropowder silica gel (adjuvant), mixing, 2500 of capsules are made in packing.Every capsules is equivalent to crude drug in whole 4g.
In the above-mentioned preparation method, the extracting method of described Radix Salviae Miltiorrhizae is lixiviate, and extraction time can be 1～3 time, and extraction time can be 0.5～2 hour, and wherein the used concentration of alcohol of alcohol extraction can be 80～95%, and water temperature raising degree can be 20～80 ℃; Described all the other five kinds of used concentration of alcohol of medicinal material extract can be 40～95%, and extraction time can be 1～3 time, and extraction time can be 0.5～2 hour; Described amount of water can be 1～4 times of all the other five kinds of medical material gross weights; The used concentration of alcohol of described eluant can be 50～95%; Described adjuvant can be acceptable accessories (for example starch, lactose, micropowder silica gel, Pulvis Talci etc.), Chinese medicine of the present invention can be made multiple dosage form.
Medicine by above method preparation, after testing, the tanshinone rate of transform is 55.1%, and the rate of transform of peoniflorin is 86.3%, and the rate of transform of lovastatin is 75.9%, the rate of transform of ursolic acid is 89.6%, and paste-forming rate reduces to 6.21% by 25.7%, shows that this preparation technology is scientific and reasonable, has kept main effective ingredient in the medicine, simultaneously significantly reduce dose, reached purified purpose.
Fatty liver, hyperlipemia belong to categories such as the traditional Chinese medical science " blood stasis ", " expectorant is turbid ", the many because eating and drinking without temperance of its morbidity, surfeit rich and fatty diet, and disorder of the spleen and stomach caused by internal damage, dysfunction of the spleen in transportation, it is precise and tiny that water paddy can not transform, poly-and be that expectorant is turbid, for cream is fat; Owing to be addicted to drink excessively, disorder of emotion can cause depression and stagnation of QI on the other hand, and hematogenous blockage again can perverse and unreasonable manner gram spleen, makes dysfunction of the spleen in transportation, and interior living expectorant is turbid, finally makes in the long-pending liver of the too much turbid fat stasis of blood and sends out.
Medicine of the present invention provides a kind of new medication to select for clinical treatment fatty liver, hyperlipemia, obesity and arteries are atherosis.
Below prove the beneficial effect of Chinese medicine of the present invention by pharmacodynamics test, toxicology test.
Test example 1: the present invention is to the influence of the high fat fatty liver of rat model
By confirming with the contrast of the pharmacological testing of DONGBAO GANTAI PIAN, simvastatin crude drug, medicine of the present invention is used for that fatty liver, hyperlipemia, obesity and arteries are atherosis to have a significant pharmacologically active.
1. test material
Medicine: medicament capsule of the present invention is pressed the preparation of embodiment 1 method, and hereinafter to be referred as the DZK capsule, the 0.25g/ grain is equivalent to crude drug in whole 4g, and promptly every gram capsule medicated powder is equivalent to crude drug in whole 16 grams.DONGBAO GANTAI PIAN, simvastatin are faced the suspension that all is made into desired concn with 0.5% (percentage by weight) CMC-Na (sodium carboxymethyl cellulose) with preceding.
Reagent: methylthiouracil, TC test kit, TG test kit, free fatty test kit, Coomassie brilliant blue test kit, SOD test kit, MDA test kit, CCl
4, sodium carboxymethyl cellulose, dehydrated alcohol, acetone.
Animal: 90 of rats, body weight 150-180g, male; Provide (the quality certification number: SCXK (Shanghai) 2003-0002) by Shanghai west pul-Bi Kai laboratory animal company limited.
Instrument: automatic clinical chemistry analyzer, Japan produces Hitachi's 7020 types; 722 visible spectrophotometers, Shanghai precision instrument company limited; Analytical electron balance TG328A, Shanghai balance equipment factory.
2. experimental control
(1) normal control group, model group give equal-volume 0.5%CMC-Na (for being subjected to reagent and positive control drug solvent).
(2) positive controls (DONGBAO GANTAI group, simvastatin group).
3. test grouping, dosage and approach
Rat is divided into 9 groups at random by blood lipid level, and 10 every group, that is: the normal control group gives 0.5%CMC-Na, and 1 group, 2 groups; The hyperlipidemia model group gives 0.5%CMC-Na, and 1 group, 2 groups; DONGBAO GANTAI group (1g.kg-1); Simvastatin group (7mg.kg
-1); DZK capsule low dose group (0.1g.kg
-1); Dosage group (0.2g.kg in the DZK capsule
-1); DZK capsule in high dose group (0.4g.kg
-1).
The above-mentioned laboratory animal of respectively organizing is all with gastric infusion, and once a day, the administration volume is 10mlkg
-1
4. statistical procedures
Data are represented (X ± SD) with mean ± standard deviation.And normal control group, model group relatively adopt mean t check between two groups.
5. test method and result
The DZK capsule is to the protective effect experimental technique of high fat rat fat liver model
90 of SD rats, male, normally raise the back fasting of 1 week, eye socket is got blood, separation of serum, (TC, TG), and according to the blood fat random packet, experiment is established: 20 of normal control groups, 70 of model group to measure blood fat.Normal group is raised with normal feedstuff, each animal subcutaneous injection 40%CCl of model group
4Fluid (3ml/kg) is once raised with high lipid food simultaneously.The high lipid food prescription is: Adeps Sus domestica 10%, and methylthiouracil 0.2%, bovine bile 0.5%, cholesterol 1%, yolk powder 3%, all the other are basic powder.Record animal consumption appetite claims body weight weekly one time.Modeling is randomly drawed normal each 10 of the model group animals that reach during 6 weeks, puts to death behind the fasting 12h, calculates the heavy coefficient of liver, measures the success or not of liver fat monitoring model, and other gets the part liver and places formalin to fix, for histopathologic examination.After the model success, model group residue animal fasting 12h posterior orbit is got blood, the mensuration blood fat (TC, TG), the model group animal is divided into 6 groups at random according to blood fat, be respectively model group (0.5%CMC-Na solution), DZK capsule in high dose group (0.4g/10ml/kg), dosage group (0.2g/10ml/kg) in the DZK capsule, low dose group (0.1g/10ml/kg), DONGBAO GANTAI group (1g/10ml/kg), simvastatin group (7mg/10ml/kg).Each treated animal gastric infusion, once a day, record animal consumption appetite claims body weight weekly one time.After 4 weeks of administration, weigh behind the fasting 12h, eye socket is got blood, separation of serum, measure blood fat (TC, TG, HDL, LDL, VLDL), SOD in serum and MDA, put to death animal simultaneously, get liver, claim liver heavy, get the part liver and place ethanol: the solution of acetone=1: 1, make 10% liver homogenate, get supernatant after the standing over night, testing index (TC, TG, HDL, LDL, VLDL).Get the part liver and place normal saline solution, make 10% liver homogenate, get supernatant, measure liver FFA.Get part liver dewatering and defatting in ethanol acetone, be used to measure the hydroxyproline content of liver after the oven dry.Other gets the part liver and places formalin fixing, for histopathologic examination.
The DZK capsule sees Table 1,2,3,4,5 to high fat rat model blood fat reducing result of the test.
5.1 result of the test
5.1.1 blood fat, liver fat change
As can be seen from Table 1, the normal treated animal of the heavy coefficient of model group animal liver has extremely significantly rising (p＜0.01), and each administration group liver macroscopic score is significantly better than model group.
Table 1.DZK capsule is to effect (X ± SD) (n=10) of heavy coefficient of high fat rat fat liver model liver and liver scoring
| Group | Dosage (g/kg) | The heavy coefficient (g/100g) of liver | The liver macroscopic score |
| Normal model DZK capsule simvastatin DONGBAO GANTAI | 0.1 0.2 0.4 0.007 1.0 | 2.531±0.131** 3.708±0.344 3.694±0.277 3.561±0.381 3.696±0.462 3.430±0.376 3.553±0.308 | 0.050±0.150** 3.500±0.500 2.900±0.831* 2.400±0.663** 2.700±0.640** 2.200±0.980** 2.300±0.458** |
* P＜0.01; * P＜0.05 is compared with model group;
As can be seen from Table 2, compare with normal group, the model group serum TC, TG, LDL, the VLDL level has remarkable rising (p＜0.01, p＜0.05).Compare with model group, DZK capsule in high dose group (0.4g/kg) serum TC has remarkable reduction (p＜0.05); The DZK capsule is low, in, high dose group (0.1,0.2,0.4g/kg) remarkable reduction (p＜0.01, p＜0.05) is arranged with simvastatin group (0.007g/kg) serum TG; DZK capsule low dose group (0.1g/kg) serum hdl has remarkable rising (p＜0.05); DZK capsule in high dose group (0.4g/kg) and simvastatin group (0.007g/kg) serum LDL have remarkable reduction (p＜0.01, p＜0.05); The DZK capsule is low, in, (0.1,0.2,0.4g/kg) serum VLDL level has remarkable reduction (p＜0.01, p＜0.05) to high dose group.
Table 2.DZK capsule is to effect (X ± SD) (n=10) of high fat rat fat liver animal pattern blood fat
| Group | Dosage (g/kg) | TCHO (mmol/l) | TG (mmol/l) | HDL (mmol/l) | LDL (mmol/l) | V-LDL (mmol/l) |
| Normal model DZK group DONGBAO GANTAI simvastatin | 0.1 0.2 0.4 1.0 0.007 | 1.37±0.12* 1.72±0.37 1.76±0.26 1.74±0.40 1.39±0.25* 1.79±0.39 1.63±0.24 | 0.70±0.13* 0.80±0.08 0.65±0.07** 0.58±0.11** 0.69±0.11* 0.78±0.14 0.70±0.11* | 0.70±0.08 0.66±0.09 0.80±0.11* 0.74±0.10 0.65±0.14 0.76±0.13 0.74±0.17 | 0.35±0.07** 0.70±0.31 0.67±0.19 0.74±0.30 0.43±0.12** 0.67±0.31 0.45±0.12* | 0.32±0.06* 0.37±0.04 0.29±0.03** 0.26±0.05** 0.31±0.05* 0.35±0.07 0.44±0.16 |
* P＜0.01; * P＜0.05 is compared with model group
As can be seen from Table 3, compare with normal group, model group liver TC, TG, LDL, HDL, the VLDL level has extremely significantly raise (p＜0.01).Compare with model group, in the DZK capsule, (0.2,0.4g/kg) DONGBAO GANTAI group (1g/kg) and simvastatin group (0.007g/kg) liver TC have remarkable reduction (p＜0.01, p＜0.05) to high dose group; DZK capsule in high dose group (0.4g/kg) and DONGBAO GANTAI group (1g/kg) liver TG have remarkable reduction (p＜0.05); In the DZK capsule, (0.2,0.4g/kg), DONGBAO GANTAI group (1g/kg) and simvastatin group (0.007g/kg) liver LDL have remarkable reduction (p＜0.01, p＜0.05) to high dose group; DZK capsule in high dose group (0.4g/kg) and simvastatin group (0.007g/kg) liver VLDL level have remarkable reduction (p＜0.05).
Table 3.DZK capsule is to effect (X ± SD) (n=10) of high fat rat fat liver animal pattern liver fat
| Group | Dosage (g/kg) | TC (mmol/l) | TG (mmol/l) | HDL (mmol/l) | LDL (mmol/l) | VLDL (mmol/l) |
| Normal model DZK capsule DONGBAO GANTAI simvastatin | 0.1 0.2 0.4 1.0 0.007 | 1.09±0.45** 2.67±0.41 2.23±0.65 2.06±0.67* 1.52±0.45** 2.03±0.49** 1.67±0.73** | 0.96±0.12** 1.79±0.52 1.31±0.41 1.67±0.43 1.59±0.55* 1.28±0.28* 1.24±0.87 | 0.10±0.05** 0.21±0.04 0.18±0.05 0.19±0.09 0.20±0.05 0.21±0.04 0.18±0.08 | 0.55±0.40** 1.65±0.40 0.74±0.29 1.28±0.58* 1.14±0.49** 1.24±0.42* 0.92±0.43** | 0.44±0.05** 0.81±0.23 0.60±0.18 0.76±0.20 0.72±0.25* 0.58±0.13* 0.57±0.39 |
* P＜0.01; * P＜0.05 is compared with model group
As can be seen from Table 4, compare with normal group, model group animal serum MDA and liver FFA level all have remarkable rising, and the SOD in serum level has remarkable decline (p＜0.05).Compare with model group, the DZK capsule is low, in, high dose group (0.1,0.2,0.4g/kg) remarkable rising (p＜0.01, p＜0.05) is arranged with simvastatin group (0.007g/kg) SOD in serum; In the DZK capsule, and high dose group (0.2,0.4g/kg) remarkable reduction (p＜0.01, p＜0.05) is arranged with simvastatin group (0.007g/kg) serum MDA; The DZK capsule is low, in, (0.1,0.2,0.4g/kg), DONGBAO GANTAI group (1g/kg) and simvastatin group (0.007g/kg) liver free fatty contain heavily extremely significantly descend (p＜0.01, p＜0.05) to high dose group.
Show the 4.DZK capsule to high fat rat model SOD in serum, MDA and liver FFA, the effect of hydroxyproline (X ± SD) (n=10)
| Dosage (g/kg) | SOD in serum (nmol/ml) | Serum MDA (nmol/ml) | Liver FFA (umol/gprot) | Liver hydroxyproline (ug/mg) | |
| Normal model DZK capsule DONGBAO GANTAI simvastatin | 0.1 0.2 0.4 1.0 0.007 | 266.16±25.58* 235.65±34.59 264.57±21.54* 263.90±18.90* 270.45±22.35* 248.76±23.45 264.80±22.68* | 6.04±0.71* 6.62±0.40 6.85±1.27 5.36±1.22** 4.62±2.25* 6.17±1.66 6.04±0.69* | 601.40±117.35* 701.76±76.22 466.75±178.86** 439.74±97.50** 388.07±156.47** 532.19±209.04* 478.18±198.32** | 1.42±0.32 1.67±0.58 1.48±0.46 1.24±0.28 1.33±0.27 1.33±0.23 1.57±0.41 |
* P＜0.01; * P＜0.05 is compared with model group
5.1.2 morphological change
Pathological section is the result show: normal group lobules of liver structure is clear, and the liver rope is radial arrangement.Model group lobules of liver structure is unclear, liver rope arrangement disorder, and hepatocyte presents steatosis in various degree.Compare with model group, high, medium and low dosage group of DZK capsule and DONGBAO GANTAI group, the simvastatin morphological change more all has improvement than model group.The results are shown in Table 5.
Table 5.DZK capsule is to the influence of the dirty therapeutical effect pathology of hyperlipidemia model animal Hepar Mus result of the test
* P＜0.01; * P＜0.05 is compared with model group
The acute toxicity test of test example 2 medicament capsules of the present invention
1. test material
1.1 medicine: medicament capsule of the present invention is pressed the preparation of embodiment 1 method, and hereinafter to be referred as the DZK capsule, the 0.25g/ grain is equivalent to crude drug in whole 4g, and promptly every gram capsule medicated powder is equivalent to crude drug in whole 16 grams.DZK capsule dry powder is made into the suspension of maximum administration concentration with 0.5%CMC-Na solution, and maximum administration concentration is 380mg/ml.
1.2 animal
The source: ICR kind white mice, cleaning level, (SHANGHAI SIPPER-BK LAB ANIMAL CO. LTD.) provides, the animal quality certification number: SCXK (Shanghai) 2003-0002 by west, Shanghai pul-Bi Kai laboratory animal company limited.Body weight: 18～22g; Sex: male and female half and half; Fasting time: 12 hours; Every treated animal number: 20.
1.3 dosage
According to trial test, find that DZK capsule gastric infusion is very little to the toxicity of mice, do not see yet that under 15g/kg dosage animal has dead the generation.Therefore, carry out the maximum test with maximum administration capacity (1.0ml/20g) and maximum administration concentration (380mg/ml) administration at last, the dosage of this moment is 19g/kg.Every animals received capacity: 1.0ml/20g
1.4 test method
The DZK capsule by above-mentioned dosage ig administration, is write down various poisoning symptoms of mice and death condition, and dead animal performs an autopsy on sb.
Toxic reaction: mainly observe the mice behavior, nervous system has or not abnormal phenomena.
The animal postmortem: the main organs to the corpse of dead animal is carried out perusal, sees to have or not tangible hyperemia, necrosis or other abnormal conditions.
Observation period: observed 14 days continuously after the administration, observe and write down death toll and the active situation of animal.
1.5 result
Behind the mice igDZK capsule, animal shows phenomenons such as activity reduces to some extent, gradually recovers normal subsequently.Animal does not have death.After about 24 hours of the administration, behavior, movable basic the recovery normally.Body weight gain normal (the results are shown in Table 6) shows no obvious abnormalities symptom in 14 day observation period afterwards.
1.6 conclusion
Under maximum administration capacity and maximum administration concentration condition, mice igDZK capsule dosage is 19g/kg, and animal does not have death, and the behavior performance has slight change, does not see obvious toxic reaction.
Death condition and body weight change situation behind the table 6 mice igDZK capsule
| Dosage (g/kg) | The dead distribution (only/day) | Body weight change situation (g) | |||||||||
| d1 | d2 | d3 | d5 | d7 | d14 | d0 | d1 | d3 | d7 | d14 | |
| 19(20) * 19(10♀) 19(10♂) | - - - | - - - | - - - | - - - | - - - | - - - | 19.3±0.9 18.9±0.9 19.6±0.8 | 19.4±0.9 19.0±0.7 19.8±0.9 | 21.4±0.8 21.0±0.7 21.8±0.6 | 24.7±1.5 23.4±0.8 25.9±0.7 | 28.4±2.4 26.2±0.6 30.5±1.4 |
* annotate: be animal example number in the bracket
By above-mentioned pharmacodynamics test and toxicity study test, prove absolutely that Chinese medicine of the present invention is evident in efficacy in diseases such as treatment fatty liver, hyperlipemia, obesity and arteries are atherosis, toxic and side effects is little, provides a kind of new medication to select for clinical.
Claims (4)
1, a kind of compound Chinese medicinal preparation for the treatment of fatty liver and hyperlipemia is characterized in that it is that following row raw materials by weight percent is made: Radix Salviae Miltiorrhizae 10～40%, Fructus Crataegi 5～30%, Rhizoma Alismatis 10～35%, the Radix Astragali 5～20%, the Radix Paeoniae Alba 5～15%, Monas cuspurpureus Went 3～20%.
2, the preparation method of the described compound Chinese medicinal preparation of claim 1 is characterized in that taking by weighing Chinese crude drug Radix Salviae Miltiorrhizae, Fructus Crataegi, Rhizoma Alismatis, the Radix Astragali, the Radix Paeoniae Alba and Monas cuspurpureus Went; Extract red rooted salvia with ethanol or aquiferous ethanol earlier, filter, get filtrate A; Reuse water extraction medicinal residues filter, and get liquor B; With ethanol or aquiferous ethanol co-extracted Fructus Crataegi, Rhizoma Alismatis, the Radix Astragali, the Radix Paeoniae Alba and Monas cuspurpureus Went medical material, filter, get liquor C; Reclaim ethanol from liquor C, concentrate extractum D; D adds entry to extractum, leaves standstill, and is centrifugal, gets supernatant E and precipitation F, will precipitate the F drying, as active ingredient I; Supernatant E and liquor B are merged, by resin column, wash with water earlier to the molish reaction and be negative, it is colourless that reuse ethanol or aquiferous ethanol are washed till effluent, collects eluent, this eluent is merged with filtrate A, and recovery ethanol, concentrate drying is as active ingredient II; Active ingredient I and II are mixed, pulverize.
3, the application of the described compound Chinese medicinal preparation of claim 1 in the medicine of preparation treatment fatty liver.
4, the application of the described compound Chinese medicinal preparation of claim 1 in the medicine of preparation treatment hyperlipemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100421660A CN1299733C (en) | 2005-03-15 | 2005-03-15 | Chinese medicine and its preparing method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100421660A CN1299733C (en) | 2005-03-15 | 2005-03-15 | Chinese medicine and its preparing method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1682994A CN1682994A (en) | 2005-10-19 |
| CN1299733C true CN1299733C (en) | 2007-02-14 |
Family
ID=35262613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100421660A Active CN1299733C (en) | 2005-03-15 | 2005-03-15 | Chinese medicine and its preparing method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1299733C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579435B (en) * | 2008-05-15 | 2011-04-20 | 北京北大维信生物科技有限公司 | Medicinal composition for treating adiposity and preparation method thereof |
| CN102058099B (en) * | 2009-11-13 | 2013-12-25 | 金士力佳友(天津)有限公司 | Health care food for losing weight |
| CN102670874B (en) * | 2011-03-14 | 2016-01-06 | 福建省医学科学研究院 | A kind of to medicative compound preparation of fatty liver and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1524540A (en) * | 2003-02-28 | 2004-09-01 | 唐山康琳药业有限公司 | Chinese medicine preparation for treating fatty liver and its preparation method |
-
2005
- 2005-03-15 CN CNB2005100421660A patent/CN1299733C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1524540A (en) * | 2003-02-28 | 2004-09-01 | 唐山康琳药业有限公司 | Chinese medicine preparation for treating fatty liver and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1682994A (en) | 2005-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1836720A (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN1058614C (en) | Galenic composition | |
| CN1299733C (en) | Chinese medicine and its preparing method and use | |
| CN1256133C (en) | Antifatigue Chinese medicine composition and its prepn process | |
| CN100341547C (en) | Medicinal composition for regulating blood fat, prepn. method and use thereof | |
| CN1478508A (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1899448A (en) | Chinese medicine compound preparation for treating amblyopia and its preparing method | |
| CN1733025A (en) | Pharmaceutical composition for treating rheumatic and rheumatoid diseases and its preparation process | |
| CN101041037A (en) | Drug for curing diabetes and nephropathy and its preparing method | |
| CN1256967C (en) | Health-preserving liver-protecting drug and method for making same | |
| CN1197614C (en) | Chinese medicine cap sule for treating prostatic disorders | |
| CN1276767C (en) | Traditional Chinese medicine for treating non-alcoholic simple fatty liver and its preparation method | |
| CN1207044C (en) | Antilipemic antiatherosclerosis medicine composition and preparing method, application thereof | |
| CN1682780A (en) | Medicine for treating uaemia and insufficiency of kidney-yang and kidney exhaustion and its preparing method | |
| CN1695715A (en) | Medication for treating dementia in blood vessel type, and preparation method | |
| CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
| CN1182864C (en) | Medicine for vascular denmentia disease and preparation method | |
| CN1927289A (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and its preparation | |
| CN101062314A (en) | Medicine for curing gout and its preparing method | |
| CN1911285A (en) | Medicine for treating adiposis hepatica, and its prepn. method | |
| CN1202854C (en) | Chinese medicine possessing kidney supplementing brain fortifying, statis transforming and vessel freeing actions | |
| CN100340267C (en) | Chinese medicinal preparation for treating fattly liver | |
| CN1562100A (en) | Medicine for treating alcohol liver damage and its preparing method | |
| CN1244339C (en) | Chinese medicine for treating and preventing fatty liver and its preparing process | |
| CN1895346A (en) | Chinese-medicinal preparation for treating cardivascular and cerebrovascular diseases and its making method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 266000 Qingdao, Shandong Province, Qingdao City, Pingdu City, New River ecological chemical technology industry base, No. 6 Patentee after: Haopu Medicine Research Co., Ltd., Qingdao Address before: 266111 Shandong Province, Qingdao city Chengyang District Green Industrial Park Patentee before: Haopu Medicine Research Co., Ltd., Qingdao |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211111 Address after: 266000 No. 6, cuishui Road, Xinhe ecological chemical technology industry base, Pingdu City, Qingdao City, Shandong Province Patentee after: Qingdao Haopu Technology Co., Ltd Address before: 266000 No. 6, cuishui Road, Xinhe ecological chemical technology industry base, Pingdu City, Qingdao City, Shandong Province Patentee before: Qingdao Haopu Pharmaceutical Research Co., Ltd |